Combining New Treatment MQ710 With Pembrolizumab for Advanced Solid Tumors

Recruiting · Phase 1 · Cutaneous Squamous Cell Carcinoma and related conditions · New Jersey and New York

Check if I qualify View on ClinicalTrials.gov

About this trial

This study is looking at how well a new treatment called MQ710 works with another medicine called pembrolizumab for people with advanced solid tumors. Participants must have cancer that has not responded to standard treatments or for which no standard treatment is available. The goal is to find the highest dose of MQ710 that causes few side effects while helping to treat the cancer.

The trial's ID number is NCT05859074. This is a Phase 1 trial, which means it's looking at how safe the treatments are and how well they work. The trial is FDA-regulated, and it aims to include about 56 participants.

Who can join

Adults aged 18 and older can join the trial. It's open to men and women with certain types of advanced or metastatic cancers that have not improved after standard treatments. The trial team will check to see if each person meets the requirements before they can participate.

Conditions

Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor

Age group

Adult, Older adult

Sex

All sexes

The study team makes the final call on eligibility.

What happens in the study

Everyone in the trial will receive either MQ710 alone or MQ710 combined with pembrolizumab. Participants will not be randomly assigned to groups; they will be placed in groups based on specific needs. The MQ710 will be injected directly into their tumors, and pembrolizumab will be given through an IV every three weeks.